1101 - An overview of young chronic lymphocytic leukemia patients: a single centre experience of 117 cases from northern India

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Leukaemia
Cancer in Young Adults
Presenter Ajay Gogia
Authors A. Gogia1, A. Sharma2, V. Raina3, L. Kumar1, R. Gupta4, R. Kumar4
  • 1Medical Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Dept. Of Medical Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 3Dept. Of Medical Oncology & Haematology & Stem Cell Transplant, All India Institute of Medical Sciences (AIIMS)Institute Rotary Cancer Hospital, IN-110029 - New Delhi/IN
  • 4Lab Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN

Abstract

Background

In this study, the clinical characteristics, survival, and prognostic factors of 117 cases of young ( = < 55 years) chronic lymphocytic leukemia (CLL) patients were analysed at IRCH, AIIMS, a large tertiary care centre of Northern India.

Methods

Patients records collected from computer database using ICD code (C-91.1) between period of 2000-2010 were retrospectively evaluated.

Results

Over a period of 11 years, 285 CLL patients (117 [41.05%] = < 55 years of age and 168 [58.95%] > 55 years of age) were evaluated. There were similar distribution of sex, lymphadenopathy, organomegaly, and absolute lymphocyte count in both groups At diagnosis, younger patients were less incidentally detected (p < .0001), more B- symptoms (p = 0.001) and advanced Rai stage ( p = 0.021), than older patients. Response rate and toxicity profile were same in both groups with chlorambucil and fludarabine based chemotherapy. Overall response rate (ORR) seen with chlorambucil and fludarabine was 69% and 88% with complete remission (CR) rate was 3% and 44 % respectively. Richter's transformation was significantly higher in younger patients (3.41% v 0.5%; p = 0.001). Median follow up period was 36 months. Younger and older patients showed a similar overall median survival but were characterized by a different distribution of causes of deaths. CLL unrelated deaths predominated in the older age group, as one third of patients have different co-morbities like diabetes, hypertension, coronary artery disease e.t.c, whereas the disease related death were prevalent in the younger age group. Multivariate analysis showed that for young CLL patients, advanced clinical stage (Rai III and IV) was associated with poor overall survival [HR 2.08 (95% CI 1.19-4.11) p = 0.001].

Conclusion

Forty one percent our CLL population was young. Young CLL patients presented with more B symptoms and advanced stage (Rai III and IV) than elderly CLL patients.

Disclosure

All authors have declared no conflicts of interest.